iRhythm Technologies stock surged 17% after receiving FDA clearance for Zio AT cardiac monitoring device, addressing past setbacks and design updates. The approval enhances compliance and patient outcomes, showcasing the company's commitment to digital health innovation. Investors are optimistic about the company's future growth and market position.